scholarly journals Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine

2021 ◽  
Author(s):  
Agnieszka Adamska ◽  
Paulina Tomczuk-Bobik ◽  
Anna Beata Poplawska-Kita ◽  
Katarzyna Siewko ◽  
Angelika Buczyńska ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Ovarian Reserve ◽  
Radioactive Iodine ◽  
Premenopausal Women ◽  
Serum Levels ◽  
Inhibin B ◽  
Serum Concentrations ◽  
Papillary Thyroid ◽  
One Year

Treatment with radioactive iodine (RAI) in women with differentiated thyroid cancer is associated with decreased serum concentrations of anti-Müllerian hormone (AMH); however, other markers have not been investigated. Therefore, this study aimed to evaluate the effect of RAI on antral follicle count (AFC) and the serum concentration of inhibin B, follicle-stimulating hormone (FSH), and AMH in women with papillary thyroid cancer (PTC) treated with RAI. We examined 25 women at a median age of 33 years treated with a single dose of RAI. We divided the participants into women over (n = 11) and under 35 years of age (n = 14). Serum concentrations of inhibin B, FSH, AMH, and AFC were assessed at baseline and one year after RAI treatment. We found decreased AFC (p = 0.03), serum levels of AMH (p < 0.01), inhibin B (p = 0.03), but not FSH (p = 0.23), one year after RAI treatment in comparison to baseline in the whole group. When we compared serum levels of AMH in younger vs. older women separately, we observed a significant reduction of this hormone’s serum level after RAI treatment in both groups (p < 0.01; p = 0.04, respectively). We concluded that RAI treatment significantly impacts the functional ovarian reserve in premenopausal women with PTC.

scholarly journals Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Tomasz Stępień ◽  
Mateusz Brożyna ◽  
Krzysztof Kuzdak ◽  
Ewelina Motylewska ◽  
Jan Komorowski ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Protease Inhibitor ◽  
Papillary Thyroid Cancer ◽  
Preoperative Diagnosis ◽  
Secretory Leukocyte Protease Inhibitor ◽  
Control Group ◽  
Serum Concentrations ◽  
Papillary Thyroid ◽  
Blood Samples ◽  
Protease Nexin

Introduction. SERPINE2 and secretory leukocyte protease inhibitor (SLPI) are proteins with anticoagulant properties which could promote solid tumor growth. However, their role in the pathogenesis of thyroid cancer has not been determined. Materials and Methods. The aim of this study was to assess serum SERPINE2 and SLPI concentrations in a group of 36 patients with papillary thyroid cancer (PTC) and a group of 19 subjects with multinodular nontoxic goiter (MNG). The control group (CG) consisted of 20 healthy volunteers. Blood samples were collected one day before surgery. Serum SERPINE2 and SLPI concentrations were measured using specific ELISA methods. Results. Significantly higher concentrations of SERPINE2 and SLPI were found in patients with PTC as compared with MNG and controls. Positive correlation was found between SERPINE2 and SLPI concentrations in PTC patients. The levels of SERPINE2 and SLPI did not differ significantly between MNG and healthy controls. Conclusions. Our results indicate that SERPINE2 and SLPI play a significant role in the development of papillary thyroid cancer and imply that the evaluation of serum concentrations of both anticoagulant molecules may be considered as additional marker for the differentiation of malignancies during the preoperative diagnosis of patients with thyroid gland tumors.

Sign in / Sign up

Export Citation Format

Share Document